Clinical trial
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 · University of California, Los Angeles, Other · Completed
Key facts
| NCT number | NCT00330551 |
|---|---|
| Title | Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia |
| Official title | Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia |
| Lead sponsor | University of California, Los Angeles, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH Janssen Scientific Affairs, LLC Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta) |
| Enrollment | 126 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | May 29, 2006 |
| Last update posted | Mar 1, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: